1 reports of this reaction
2.1% of all AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE reports
#9 most reported adverse reaction
CYSTITIS is the #9 most commonly reported adverse reaction for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 1 FDA adverse event reports linking AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE to CYSTITIS. This represents approximately 2.1% of all 48 adverse event reports for this drug.
Patients taking AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE who experience cystitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTITIS is a less commonly reported adverse event for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to cystitis, the following adverse reactions have been reported for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE:
The following drugs have also been linked to cystitis in FDA adverse event reports:
CYSTITIS has been reported as an adverse event in 1 FDA reports for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTITIS accounts for approximately 2.1% of all adverse event reports for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE, making it a notable side effect.
If you experience cystitis while taking AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.